List of Shandong Weifang Pharmaceutical Factory APIs

Country: China

Supplier Description: Shandong Weifang Pharmaceutical Factory Co., Ltd. was established in 1966 and occupies a total area of 16,500 square meters, including 14,600 square meters of construction space. The company employs 382 staff members, among whom are 112 technicians and 11 licensed pharmacists. The company operates five modern GMP pharmaceutical workshops dedicated to the production of water injectables, sterile powder injections, tablets, capsules, and APIs. All five workshops have passed Chinese GMP certification. Its Captopril API workshop was approved by the U.S. FDA in 1998 and successfully passed a cGMP reinspection in 2004, making it the only facility in China at that time to have passed an FDA inspection. In 2007, the company also obtained the European Certificate of Suitability (COS) for its Captopril API. Shandong Weifang Pharmaceutical Factory Co., Ltd. manufactures five major product series encompassing 74 varieties and 116 specifications. Its annual production capacity includes 100 million water injectables, 52 million powder injections, 500 million tablets, 1.5 billion capsules, and 150 tons of raw materials. Key products include APIs such as Captopril, Enalapril, Lisinopril, Gemfibrozil, Lomustine, Hydralazine Hydrochloride, Acetylglutamine, as well as a range of finished dosage formulations. The company maintains established business relationships with numerous international partners for both APIs and finished formulations. These partners include Rolabo, Sanofi-Synthelabo, Teva Pharmaceutical, Helm AG, Midas Pharmaceutical, Aceto Ltd., Hikma Pharmaceutical, Biogal Pharmaceutical, West-Ward Pharmaceuticals, LCM S.P.A., Zeta Pharmaceutical, and Worwag GmbH, among others. - Show More